1H-pyrrolo[2,3-b]pyridin-3-ol | 1258406-15-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1H-pyrrolo[2,3-b]pyridin-3-ol
• CAS: 1258406-15-3
• 化学式: C₇H₆N₂O
• mdl: MFCD18414675
• 分子量: 134.14
• InChiKey: NVHACOHMMJMOCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
  申请人：Technische Universität Kaiserslautern

  公开号：EP2199292A1

  公开（公告）日：2010-06-23

  The present invention relates to 7-azaindirubins (1), 7'-azaindirubins (2), and 7,7'-diaza-indirubins (3), wherein E, R1 and R2 have the meanings detailed in the description, their production and use as a medicament for treating cancer, neurodegenerative diseases, bipolar disorders, inflammatory and infectious diseases, including viral diseases. Depending on structure, these indirubins act as inhibitors of various kinases involved in tumor cell growth, and, most notably, as inhibitors of human tumor cell proliferation. As compared to indirubins bearing identical substituents but no hetero atoms in position 7 and 7', the activity of the compounds according to the present invention is increased and the propensity to get metabolized by CYP450s is reduced, resulting in improved metabolic stability.

  本发明涉及7-azaindirubins（1）、7'-azaindirubins（2）和7,7'-二氮杂吲哚（3），其中E、R1和R2的含义在描述中有详细说明，它们的制备和用作治疗癌症、神经退行性疾病、躁郁症、炎症和传染病，包括病毒性疾病的药物。根据结构的不同，这些吲哚作为抑制与肿瘤细胞生长有关的各种激酶的作用，尤其是作为人类肿瘤细胞增殖的抑制剂。与携带相同取代基但在位置7和7'没有杂原子的吲哚相比，根据本发明的化合物的活性增加，且通过CYP450酶代谢的倾向减少，从而提高了代谢稳定性。
• SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS
  申请人：Blaney Jeffrey M.

  公开号：US20090005356A1

  公开（公告）日：2009-01-01

  Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

  本文提供了取代的吡咯吡啶杂环和取代的吡唑吡啶杂环，以及包含这些杂环的制药组合物以及使用这些杂环治疗疾病的方法。本文所披露的杂环可作为激酶调节剂，并在治疗癌症、过敏、哮喘、炎症、阻塞性呼吸道疾病、自身免疫疾病、代谢性疾病、感染、中枢神经系统疾病、脑肿瘤、肥胖症、哮喘、血液疾病、退行性神经疾病、心血管疾病或与血管生成、新生血管或血管生成有关的疾病中具有实用价值。
• 7-AZAINDIRUBINS, 7'-AZAINDIRUBINS, 7-7'-DIAZAINDIRUBIN AND THE CORRESPONDING 3'-OXIME ETHER DERIVATES: PRODUCTION THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT
  申请人：Eisenbrand, Gerhard

  公开号：EP2379549B1

  公开（公告）日：2016-09-21
• 7-AZAINDIRUBINS, 7'AZAINDIRUBINS, 7,7'-DIAZAINDIRUBINS AND THE CORRESPONDING 3'-OXIME ETHER DERIVATIVES THEREOF, THEIR PRODUCTION AND USE AS A MEDICAMENT
  申请人：Eisenbrand, Gerhard

  公开号：EP2379549A1

  公开（公告）日：2011-10-26
• COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20190263800A1

  公开（公告）日：2019-08-29

  Compounds active on the receptor protein tyrosine kinases c-kit an or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.